Second Generation
3029 Prospect Ave, Cleveland, OH, 44115, United States
Overview
Second Generation Ltd. is the Embrescia family’s investment firm focused on investing in well-managed companies and uncovering unique business opportunities. They invest in profitable, small-to-mid market companies with strong business models, proven revenue and earnings growth and the leadership position capable of sustaining that growth. They work with talented management teams to develop businesses that have potential for significant growth and they are actively involved in helping to build long-term value.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Finance
- Financial Services
- Small and Medium Businesses
Investment portfolio
- Cleveland HeartLab
Participated · Equity · Mar 2010
Cleveland HeartLab operates a CLIA-certified, CAP-accredited specialty clinical laboratory providing a proprietary five-biomarker inflammation panel anchored by its CardioMPO test to assess cardiovascular disease risk. The panel assesses distinct inflammatory pathways to provide broader prognostic coverage than traditional blood tests and to help physicians identify patients at higher risk of heart attack or stroke. CHL was spun out of Cleveland Clinic in 2009 and runs an R&D laboratory developing next-generation cardiovascular biomarkers. The company completed an $18.4 million Series B financing to support rapid growth and product development. Planned expansions include launching a dysfunctional HDL test in early 2012, expanding its proprietary test menu, in-licensing new biomarkers, and tripling its Cleveland Health‑Tech Corridor operations footprint. CHL targets a multibillion-dollar market amid high cardiovascular disease prevalence—more than 81 million Americans with some form of cardiovascular disease and roughly 750,000 annual deaths from heart disease and stroke. Cleveland HeartLab (CHL) is a Cleveland, Ohio-based clinical laboratory and disease management company that offers proprietary diagnostic tests built on molecular biomarkers. The company completed a $3.0M financing round to support growth. CHL plans to use the funds to expand its reference laboratory operations, increase selling and marketing efforts, advance its pipeline of markers such as dysfunctional HDL and nitrotyrosine, and move toward profitability. In conjunction with the financing CHL made several leadership appointments, naming Les C. Vinney chairman and Jake Orville president and chief executive. Drs. Marc Penn and Stanley Hazen were appointed chief medical officer and chief scientific officer, respectively, and an advisory board led by Dr. Penn includes William C. Popik, Michael C. Fiore, and Melissa A. Ohlson. No operating metrics or additional financial details were disclosed in the article.
Team
No current team members are available.